Clear Harbor Asset Management LLC Boosts Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Clear Harbor Asset Management LLC grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,418 shares of the medical research company’s stock after buying an additional 1,269 shares during the period. Clear Harbor Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $6,981,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the company. Charles Schwab Trust Co increased its position in shares of Thermo Fisher Scientific by 25.5% during the fourth quarter. Charles Schwab Trust Co now owns 556 shares of the medical research company’s stock worth $289,000 after purchasing an additional 113 shares in the last quarter. Aspiriant LLC increased its position in Thermo Fisher Scientific by 2.6% during the 4th quarter. Aspiriant LLC now owns 1,668 shares of the medical research company’s stock valued at $868,000 after buying an additional 43 shares in the last quarter. Reliant Investment Management LLC boosted its holdings in Thermo Fisher Scientific by 1.7% in the fourth quarter. Reliant Investment Management LLC now owns 12,246 shares of the medical research company’s stock worth $6,371,000 after acquiring an additional 200 shares in the last quarter. ZWJ Investment Counsel Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.6% during the fourth quarter. ZWJ Investment Counsel Inc. now owns 75,152 shares of the medical research company’s stock valued at $39,096,000 after acquiring an additional 1,897 shares in the last quarter. Finally, Pure Financial Advisors LLC grew its position in Thermo Fisher Scientific by 7.0% during the 4th quarter. Pure Financial Advisors LLC now owns 1,117 shares of the medical research company’s stock worth $581,000 after purchasing an additional 73 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the sale, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. This represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 47,150 shares of company stock worth $25,954,465. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 0.4 %

Shares of NYSE TMO opened at $559.72 on Tuesday. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a twelve month low of $493.30 and a twelve month high of $627.88. The stock has a market capitalization of $214.09 billion, a PE ratio of 35.09, a PEG ratio of 3.71 and a beta of 0.76. The stock has a fifty day simple moving average of $529.96 and a 200-day simple moving average of $568.56.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping the consensus estimate of $5.25 by $0.03. The firm had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm’s revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.69 earnings per share. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific declared that its board has initiated a stock repurchase program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Bernstein Bank lifted their price objective on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. TD Cowen raised their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Redburn Atlantic assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price target on the stock. Scotiabank initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 price objective on the stock. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $648.95.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.